Akebia Therapeutics Files DEFA14A Proxy Materials
Ticker: AKBA · Form: DEFA14A · Filed: Apr 28, 2026 · CIK: 0001517022
| Field | Detail |
|---|---|
| Company | Akebia Therapeutics, Inc. (AKBA) |
| Form Type | DEFA14A |
| Filed Date | Apr 28, 2026 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: proxy-filing, shareholder-materials, regulatory
TL;DR
Akebia filed extra proxy docs, shareholders get more info.
AI Summary
Akebia Therapeutics, Inc. filed a Definitive Additional Materials (DEFA14A) on April 28, 2026. This filing is related to proxy materials and does not contain specific financial figures or proposals, but rather supplementary information for shareholders.
Why It Matters
This filing indicates Akebia Therapeutics is providing additional information to shareholders regarding matters to be voted on, which could influence shareholder decisions on corporate governance or strategic initiatives.
Risk Assessment
Risk Level: low — This filing is a routine proxy material submission and does not inherently present new financial or operational risks.
Key Players & Entities
- Akebia Therapeutics, Inc. (company) — Filer of the DEFA14A
- 0001517022-26-000035 (filing_id) — SEC Accession Number for the filing
- 2026-04-28 (date) — Filing Date
FAQ
What type of SEC filing is this?
This is a DEFA14A filing, which stands for Additional definitive proxy soliciting materials and Rule 14(a)(12) material.
Who is the filer of this document?
The filer is Akebia Therapeutics, Inc., with CIK number 0001517022.
When was this filing submitted to the SEC?
The filing date was April 28, 2026.
What is the business address of Akebia Therapeutics, Inc.?
The business address is 245 FIRST STREET CAMBRIDGE MA 02142.
What is the SIC code associated with Akebia Therapeutics, Inc.?
The SIC code is 2834, which corresponds to Pharmaceutical Preparations.
Filing Details
This Form DEFA14A (Form DEFA14A) was filed with the SEC on April 28, 2026 regarding Akebia Therapeutics, Inc. (AKBA).